ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Articles
Two New Testosterone Formulations Flunk FDA Panel
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Excel Male" data-source="post: 272871" data-attributes="member: 1"><p>It's a bad day for Big Pharma when it comes to new testosterone formulations. Two new drugs, Tlando and Jatenzo did not gain approval by an FDA advisory panel. Both are oral forms of testosterone undecanoate, meant to be taken daily. The two new drugs were turned down over fears of side effects on cardiovascular health and cholesterol levels. The <a href="https://www.fiercebiotech.com/biotech/fda-panel-shoots-down-lipocine-low-testosterone-drug" target="_blank">financial press</a> has the news:</p><p></p><p></p><p></p><p>Lipocine arrived at the FDA meeting armed with data from two phase 3 trials showing Tlando moves average serum testosterone concentrations up into the normal range in most people. That result was enough for the studies to meet their primary endpoints. But the overall dataset failed to quell fears about cardiovascular adverse events and the drug’s effect on blood pressure.</p></blockquote><p></p>
[QUOTE="Excel Male, post: 272871, member: 1"] It's a bad day for Big Pharma when it comes to new testosterone formulations. Two new drugs, Tlando and Jatenzo did not gain approval by an FDA advisory panel. Both are oral forms of testosterone undecanoate, meant to be taken daily. The two new drugs were turned down over fears of side effects on cardiovascular health and cholesterol levels. The [url=https://www.fiercebiotech.com/biotech/fda-panel-shoots-down-lipocine-low-testosterone-drug]financial press[/url] has the news: Lipocine arrived at the FDA meeting armed with data from two phase 3 trials showing Tlando moves average serum testosterone concentrations up into the normal range in most people. That result was enough for the studies to meet their primary endpoints. But the overall dataset failed to quell fears about cardiovascular adverse events and the drug’s effect on blood pressure. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Articles
Two New Testosterone Formulations Flunk FDA Panel
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top